Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis.

Front Pharmacol · 2026 · PMC13290724 · PMID 42358357

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

Notably, idarubicin’s reproductive system adverse events (ROR = 4.0, PRR = 3.99, EBGM05 = 11.14) and epirubicin’s hepatobiliary toxicity (ROR = 4.99, PRR = 4.63, EBGM05 = 6.72) showed borderline significance with IC025 values of 0.28 and 0.5, respectively.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.